



Express Mail No.: EV452776538US  
Sheet 1 of 1

JUN 27 2006	ATTY. DOCKET NO. 9471-011-999	APPLICATION NO. 10/506,406
REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		
APPLICANT Swiercz et al.		
FILING DATE March 14, 2005	ART UNIT 1656	

### U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
-------------------	--	-----------------	------------------	----------------------------------------------------	------------------------------------------------------------------------------

### FOREIGN PATENT DOCUMENTS

		Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
--	--	--------------------------------------------------------------------------	------------------	----------------------------------------------------	---------------------------------------------------------------------------------	---

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
<i>HR</i>	C45	CHOROSTOWSKA-WYNIMKO et al., 2002, "Cysteine mutations of plasminogen activator inhibitory type I extend its half-life. Implication for inhibition of cancer angiogenesis." Proc. Amer. Associat. For Can. Res. Ann. Meeting, 43:141	
	C46	IM HANA et al., 2000, "Bypassing the kinetic trap of serpin protein folding by loop extension," Protein Sci. 9(8): 1497-1502	
	C47	SIMONOVIC et al., 2000, "The native metastable fold of Cl-inhibitor is stabilized by disulfide bonds." Biochimica et Biophysica Acta. 1481(1): 97-102	
<i>✓</i>	C48	TUCKER et al., 1995, "Engineering of plasminogen activator inhibitor-I to reduce the rate of latency transition," Nat. Struct. Biol. 2(6): 442-445	

EXAMINER <i>Chape Robinson</i>	DATE CONSIDERED <i>6/25/07</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	